Pepaxti study supports use in wider myeloma population

PharmaTimes

Phase 2 bridge data show consistent outcomes in patients with impaired kidney function

pharminent May 20, 2026 (Last updated: May 21, 2026)

PharmaTimes

Phase 2 bridge data show consistent outcomes in patients with impaired kidney function

Related Stories